Concepedia

Tien Hoang

TH

Statistics

Publications

38

Citations

3.5K

H-Index

26

Active since

2003

Affiliations

Roche (Switzerland)(Current)

University of Wisconsin–Madison

Sarah Cannon

Florida Hospital Cancer Institute

University of Wisconsin Carbone Cancer Center

Tien Hoang is an author at Roche (Switzerland) specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

2003–2023

38

Publications

38

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Thoracic Oncology · 2020 · 607 citations · Full text

, , +16

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio, Fabrice Barlési, Howard West et al. · Journal of Thoracic Oncology · 2020 · 458 citations · Full text

, , +11

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad et al. · The Lancet Oncology · 2017 · 343 citations · Full text

, , +15

Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data

Tien Hoang, Ronghui Xu, Joan H. Schiller et al. · Journal of Clinical Oncology · 2004 · 264 citations · Full text

, , +14

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Clinical Oncology · 2018 · 220 citations

, , +15

1–5 of 38